Innovations in Pulmonary Embolism Management: A Look at the Future
Disclaimer
This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Abstract
Pulmonary embolism (PE) remains a significant cause of cardiovascular mortality, with its incidence on the rise. Despite established guidelines, real-world clinical practice faces challenges due to patient heterogeneity and contraindications to standard therapies. This article explores the current landscape of PE management, highlighting traditional approaches, emerging therapeutic innovations such as advanced catheter-directed therapies, supportive care, and the pivotal role of multidisciplinary teams and artificial intelligence in shaping the future of PE treatment.
1. Introduction: The Evolving Landscape of Pulmonary Embolism
Pulmonary embolism (PE), a critical cardiovascular condition, stands as the third leading cause of cardiovascular death globally [1]. Its rising incidence over recent decades, primarily driven by an aging population and an increased prevalence of conditions like cancer, underscores the urgent need for continuous advancements in its management and treatment strategies [1, 2, 3]. Despite the development of clear treatment guidelines based on patient risk profiles, significant discrepancies often exist between recommended practices and real-world clinical application. These deviations frequently arise from the complex comorbidities present in PE patients, which complicate therapeutic decisions [1]. Consequently, alongside conventional standard-of-care treatments, novel and emerging therapies are continuously being explored to address these persistent challenges and improve patient outcomes. This review aims to provide a comprehensive overview of the current epidemiological trends, initial assessment strategies, established treatment options, and the most recent therapeutic innovations, thereby outlining a contemporary framework for the effective management of PE.
2. Current Approaches and Unmet Needs in PE Management
Traditional management of PE is guided by patient risk stratification, ranging from anticoagulation for low and intermediate-risk patients to systemic thrombolysis for high-risk individuals [10]. However, the application of these guidelines in clinical practice reveals several unmet needs. Systemic thrombolysis, while recommended for high-risk PE, is often underutilized, with only 12–20% of eligible patients receiving it due to contraindications or perceived high bleeding risk [1, 13, 14]. Surgical pulmonary embolectomy, an alternative for those with contraindications or failed thrombolysis, is associated with significant in-hospital mortality rates [32, 37]. These challenges highlight the necessity for more accurate risk stratification tools and alternative advanced treatments that can be safely and effectively applied across a broader spectrum of PE patients.
3. Emerging Therapeutic Innovations
3.1. Advanced Catheter-Directed Therapies (CDT)
Catheter-directed therapies (CDT) have emerged as a promising alternative, offering targeted treatment with potentially lower systemic bleeding risks compared to systemic thrombolysis. These interventions are increasingly considered for high-risk PE patients with contraindications to systemic thrombolysis, those who fail thrombolysis, or hemodynamically deteriorating low- and intermediate-risk patients [10]. CDTs have demonstrated favorable hemodynamic effects, including significant reductions in the right ventricle (RV) to left ventricle (LV) ratio and systolic pulmonary artery pressure (sPAP), alongside a good safety profile [58, 59, 60, 61, 62].
Catheter-Directed Thrombolysis (CDTL)
CDTL involves the direct infusion of thrombolytic agents into the pulmonary arteries via a catheter. Studies have shown that CDTL can reduce the RV/LV ratio and sPAP, with effects sustained over several months [64, 66]. Ongoing randomized controlled trials, such as BETULA (NCT03854266) and PE-TRACT (NCT05591118), are expected to provide more definitive evidence on the efficacy and safety of CDTL compared to standard anticoagulation [74].
Ultrasound-Assisted Catheter-Directed Therapy (UACDT)
UACDT utilizes an ultrasound core transducer within the catheter to generate an acoustic field, which enhances the dispersion of fibrinolytic agents into the clot and disaggregates the thrombus [67]. The Ekos system (Boston Scientific) is a prominent UACDT device. Clinical trials like SEATTLE II and ULTIMA have demonstrated excellent hemodynamic improvement in PE patients, with reductions in RV/LV ratio and sPAP, and a favorable safety profile [65, 68]. The ongoing HI-PEITHO trial (NCT04790370) is further investigating UACDT in intermediate-high-risk PE patients [75].
Mechanical Thrombectomy
Mechanical thrombectomy techniques aim to remove thrombi through fragmentation, aspiration, or a combination of both, often avoiding or minimizing the need for thrombolytic agents. Devices such as the BASHIR Endovascular Catheter, Indigo System (Penumbra), FlowTriever (Inari), Cleaner (Argon Medical), and AngioJet (Boston Scientific) represent various approaches in this category [59, 60, 61, 62, 71, 77, 78, 79]. The Indigo System, for instance, has shown a good safety profile with low rates of major adverse events and significant reductions in RV/LV ratio and sPAP, often without the use of thrombolytics [61]. The FlowTriever system has demonstrated significant hemodynamic improvements and a favorable safety profile in intermediate- and high-risk PE patients, with studies like FLARE and FLASH highlighting its effectiveness [58, 62]. The FLAME study even suggested lower mortality and bleeding rates with FlowTriever compared to other contemporary therapies in high-risk PE [71]. Ongoing trials like STORM-PE (NCT05684796) and CLEAN-PE (NCT06189313) are expected to provide further insights into the comparative effectiveness of these mechanical thrombectomy devices [276, 286].
3.2. Supporting Therapies
Supportive therapies are crucial in managing PE, particularly for respiratory and hemodynamic stability. Oxygen supplementation and non-invasive ventilation (NIV) are employed for hypoxemia, with NIV preferred to avoid the adverse hemodynamic effects of invasive ventilation [10]. Hemodynamic support includes cautious fluid challenges, vasopressors (e.g., noradrenaline), and positive inotropes (e.g., dobutamine) for right ventricular failure [10]. In cases of circulatory collapse or cardiac arrest, veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has proven vital in maintaining systemic perfusion and oxygenation, serving as a bridge to reperfusion or recovery [42, 43, 44, 45, 46, 47]. Veno-venous ECMO (VV-ECMO) is used for persistent severe hypoxemia even after reperfusion, improving RV function and reducing pulmonary artery resistance [48].
3.3. Anticoagulation Strategies
Anticoagulation remains the cornerstone of PE treatment for intermediate- and low-risk patients [10]. Novel oral anticoagulants (NOACs) are increasingly recommended over vitamin K antagonists (VKAs) due to their improved safety profile, particularly a reduced risk of major bleeding [51]. Specific NOACs like rivaroxaban and apixaban allow for treatment initiation with higher doses, offering non-inferior efficacy and a potentially improved benefit-risk profile compared to low-molecular-weight heparin (LMWH) or VKAs [49, 50]. Perioperative anticoagulation management requires careful balancing of VTE prevention and bleeding risk, often involving LMWH or NOAC bridging strategies [53, 54].
4. The Role of Multidisciplinary Teams: Pulmonary Embolism Response Teams (PERT)
The complexity of PE management necessitates a coordinated, multidisciplinary approach. Pulmonary Embolism Response Teams (PERT) have been established in many hospitals to provide rapid and individualized care for patients with acute PE [10, 80]. These teams, typically comprising pulmonologists, cardiologists, hematologists, intensivists, cardiothoracic surgeons, radiologists, and interventional specialists, facilitate prompt assessment, risk stratification, and timely implementation of optimal therapeutic interventions. The involvement of PERT has been associated with improved patient survival, reduced complications, and more efficient resource utilization [81, 82].
5. Integrating Current Recommendations and Future Directions
The integration of current guidelines with emerging evidence is crucial for optimizing PE management. The underutilization of systemic thrombolysis in high-risk patients and the limitations of existing treatments highlight the need for alternative advanced therapies. CDTs, with their favorable safety and hemodynamic profiles, represent a viable option for patients with contraindications to thrombolysis or those at high bleeding risk [71]. Furthermore, the development of more accurate risk stratification tools, such as the National Early Warning Score (NEWS), can aid in the early detection of patients at higher risk of hemodynamic decompensation, allowing for timely intervention [39, 40, 41]. Ongoing clinical trials are expected to provide further clarity on the optimal role of these emerging therapies in the overall management algorithm for PE.
6. The Promise of Artificial Intelligence and Machine Learning
The field of artificial intelligence (AI) and machine learning (ML) holds immense promise for revolutionizing PE management. ML models are being developed to leverage clinical data for accurate forecasting of clinical outcomes, supporting clinical decision-making with greater precision than traditional statistical methods [84]. These models can identify patients at risk of PE even before its onset, enabling earlier recognition, diagnosis, and timely treatment [84]. Furthermore, ML has been applied to identify predictors of adverse outcomes, aiding in the stratification of patients who could benefit from more intensive treatment prior to hemodynamic deterioration [85]. ML models can also enhance diagnostic accuracy and speed, particularly in the interpretation of CT scans for PE detection [87]. Collectively, these AI-driven tools have the potential to enable more tailored therapeutic strategies and significantly improve patient care.
7. Conclusion: A Brighter Future for PE Patients
Pulmonary embolism continues to pose a significant health challenge, but the landscape of its management is rapidly evolving. While traditional guidelines provide a foundational framework, the emergence of advanced catheter-directed therapies, refined supportive care, the collaborative efforts of multidisciplinary PERT teams, and the transformative potential of artificial intelligence are paving the way for a brighter future. These innovations offer more targeted, safer, and personalized treatment options, addressing the complexities of patient heterogeneity and improving outcomes for individuals affected by this life-threatening condition. Continued research and the integration of these advancements into clinical practice will be paramount in further reducing PE-related morbidity and mortality.
References
[1] Schultz J, Giordano N, Zheng H, Parry BA, Barnes GD, Heresi GA, et al. EXPRESS: A Multidisciplinary Pulmonary Embolism Response Team (PERT) - Experience from a national multicenter consortium. Pulmonary Circulation. 2019;9:2045894018824563. doi: 10.1177/2045894018824563. [DOI] [PMC free article] [PubMed] [Google Scholar] [2] Jiménez D, de Miguel-Díez J, Guijarro R, Trujillo-Santos J, Otero R, Barba R, et al. Trends in the Management and Outcomes of Acute Pulmonary Embolism: Analysis From the RIETE Registry. Journal of the American College of Cardiology. 2016;67:162–170. doi: 10.1016/j.jacc.2015.10.060. [DOI] [PubMed] [Google Scholar] [3] Wendelboe AM, Raskob GE. Global Burden of Thrombosis: Epidemiologic Aspects. Circulation Research. 2016;118:1340–1347. doi: 10.1161/CIRCRESAHA.115.306841. [DOI] [PubMed] [Google Scholar] [10] Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) European Heart Journal. 2020;41:543–603. doi: 10.1093/eurheartj/ehz405. [DOI] [PubMed] [Google Scholar] [13] Keller K, Hobohm L, Ebner M, Kresoja KP, Münzel T, Konstantinides SV, et al. Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany. European Heart Journal. 2020;41:522–529. doi: 10.1093/eurheartj/ehz236. [DOI] [PubMed] [Google Scholar] [14] Kobayashi T, Pugliese S, Sethi SS, Parikh SA, Goldberg J, Alkhafan F, et al. Contemporary Management and Outcomes of Patients With High-Risk Pulmonary Embolism. Journal of the American College of Cardiology. 2024;83:35–43. doi: 10.1016/j.jacc.2023.10.026. [DOI] [PMC free article] [PubMed] [Google Scholar] [32] Goldberg JB, Giri J, Kobayashi T, Ruel M, Mittnacht AJC, Rivera-Lebron B, et al. Surgical Management and Mechanical Circulatory Support in High-Risk Pulmonary Embolisms: Historical Context, Current Status, and Future Directions: A Scientific Statement From the American Heart Association. Circulation. 2023;147:e628–e647. doi: 10.1161/CIR.0000000000001117. [DOI] [PubMed] [Google Scholar] [37] Keeling WB, Sundt T, Leacche M, Okita Y, Binongo J, Lasajanak Y, et al. Outcomes After Surgical Pulmonary Embolectomy for Acute Pulmonary Embolus: A Multi-Institutional Study. The Annals of Thoracic Surgery. 2016;102:1498–1502. doi: 10.1016/j.athoracsur.2016.05.004. [DOI] [PubMed] [Google Scholar] [58] Toma C, Jaber WA, Weinberg MD, Bunte MC, Khandhar S, Stegman B, et al. Acute outcomes for the full US cohort of the FLASH mechanical thrombectomy registry in pulmonary embolism. EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2023;18:1201–1212. doi: 10.4244/EIJ-D-22-00732. [DOI] [PMC free article] [PubMed] [Google Scholar] [59] Bashir R, Foster M, Iskander A, Darki A, Jaber W, Rali PM, et al. Pharmacomechanical Catheter-Directed Thrombolysis With the Bashir Endovascular Catheter for Acute Pulmonary Embolism: The RESCUE Study. JACC. Cardiovascular Interventions. 2022;15:2427–2436. doi: 10.1016/j.jcin.2022.09.011. [DOI] [PubMed] [Google Scholar] [60] Moriarty JM, Dohad SY, Schiro BJ, Tamaddon H, Heithaus RE, Iliadis EA, et al. Clinical, Functional, and Quality-of-Life Outcomes after Computer Assisted Vacuum Thrombectomy for Pulmonary Embolism: Interim Analysis of the STRIKE-PE Study. Journal of Vascular and Interventional Radiology: JVIR. 2024;35:1154–1165.e6. doi: 10.1016/j.jvir.2024.04.028. [DOI] [PubMed] [Google Scholar] [61] Sista AK, Horowitz JM, Tapson VF, Rosenberg M, Elder MD, Schiro BJ, et al. Indigo Aspiration System for Treatment of Pulmonary Embolism: Results of the EXTRACT-PE Trial. JACC. Cardiovascular Interventions. 2021;14:319–329. doi: 10.1016/j.jcin.2020.09.053. [DOI] [PubMed] [Google Scholar] [62] Tu T, Toma C, Tapson VF, Adams C, Jaber WA, Silver M, et al. A Prospective, Single-Arm, Multicenter Trial of Catheter-Directed Mechanical Thrombectomy for Intermediate-Risk Acute Pulmonary Embolism: The FLARE Study. JACC. Cardiovascular Interventions. 2019;12:859–869. doi: 10.1016/j.jcin.2018.12.022. [DOI] [PubMed] [Google Scholar] [64] Sadeghipour P, Jenab Y, Moosavi J, Hosseini K, Mohebbi B, Hosseinsabet A, et al. Catheter-Directed Thrombolysis vs Anticoagulation in Patients With Acute Intermediate-High-risk Pulmonary Embolism: The CANARY Randomized Clinical Trial. JAMA Cardiology. 2022;7:1189–1197. doi: 10.1001/jamacardio.2022.3591. [DOI] [PMC free article] [PubMed] [Google Scholar] [65] Kucher N, Boekstegers P, Müller OJ, Kupatt C, Beyer-Westendorf J, Heitzer T, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation. 2014;129:479–486. doi: 10.1161/CIRCULATIONAHA.113.005544. [DOI] [PubMed] [Google Scholar] [66] Kroupa J, Buk M, Weichet J, Malikova H, Bartova L, Linkova H, et al. A pilot randomised trial of catheter-directed thrombolysis or standard anticoagulation for patients with intermediate-high risk acute pulmonary embolism. EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2022;18:e639–e646. doi: 10.4244/EIJ-D-21-01080. [DOI] [PubMed] [Google Scholar] [67] Nosher JL, Patel A, Jagpal S, Gribbin C, Gendel V. Endovascular treatment of pulmonary embolism: Selective review of available techniques. World Journal of Radiology. 2017;9:426–437. doi: 10.4329/wjr.v9.i12.426. [DOI] [PMC free article] [PubMed] [Google Scholar] [68] Piazza G, Hohlfelder B, Jaff MR, Ouriel K, Engelhardt TC, Sterling KM, et al. A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study. JACC. Cardiovascular Interventions. 2015;8:1382–1392. doi: 10.1016/j.jcin.2015.04.020. [DOI] [PubMed] [Google Scholar] [71] Silver MJ, Gibson CM, Giri J, Khandhar S, Jaber W, Toma C, et al. Outcomes in High-Risk Pulmonary Embolism Patients Undergoing FlowTriever Mechanical Thrombectomy or Other Contemporary Therapies: Results From the FLAME Study. Circulation. Cardiovascular Interventions. 2023;16:e013406. doi: 10.1161/CIRCINTERVENTIONS.123.013406. [DOI] [PMC free article] [PubMed] [Google Scholar] [74] Planer D, Yanko S, Matok I, Paltiel O, Zmiro R, Rotshild V, et al. Catheter-directed thrombolysis compared with systemic thrombolysis and anticoagulation in patients with intermediate- or high-risk pulmonary embolism: systematic review and network meta-analysis. CMAJ: Canadian Medical Association Journal = Journal De L’Association Medicale Canadienne. 2023;195:E833–E843. doi: 10.1503/cmaj.220960. [DOI] [PMC free article] [PubMed] [Google Scholar] [75] Klok FA, Piazza G, Sharp ASP, Ní Ainle F, Jaff MR, Chauhan N, et al. Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. American Heart Journal. 2022;251:43–53. doi: 10.1016/j.ahj.2022.05.011. [DOI] [PubMed] [Google Scholar] [77] Singh M, Quimby A, Lakhter V, Al-Otaibi M, Rali PM, Bashir R. Novel Pharmacomechanical Thrombolysis for Treating Intermediate-Risk Acute Pulmonary Embolism: The Bashir Endovascular Catheter. Texas Heart Institute Journal. 2021;48:e217589. doi: 10.14503/THIJ-21-7589. [DOI] [PMC free article] [PubMed] [Google Scholar] [78] Barjaktarevic I, Friedman O, Ishak C, Sista AK. Catheter-directed clot fragmentation using the Cleaner™ device in a patient presenting with massive pulmonary embolism. Journal of Radiology Case Reports. 2014;8:8:30–36. doi: 10.3941/jrcr.v8i2.1455. [DOI] [PMC free article] [PubMed] [Google Scholar] [79] Bonvini RF, Roffi M, Bounameaux H, Noble S, Müller H, Keller PF, et al. AngioJet rheolytic thrombectomy in patients presenting with high-risk pulmonary embolism and cardiogenic shock: a feasibility pilot study. EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2013;8:1419–1427. doi: 10.4244/EIJV8I12A215. [DOI] [PubMed] [Google Scholar] [80] Kabrhel C, Rosovsky R, Channick R, Jaff MR, Weinberg I, Sundt T, et al. A Multidisciplinary Pulmonary Embolism Response Team: Initial 30-Month Experience With a Novel Approach to Delivery of Care to Patients With Submassive and Massive Pulmonary Embolism. Chest. 2016;150:384–393. doi: 10.1016/j.chest.2016.03.011. [DOI] [PubMed] [Google Scholar] [81] Jaff MR, Secemsky EA. Response Team Management of Acute Serious Pulmonary Embolism. Texas Heart Institute Journal. 2021;48:e217558. doi: 10.14503/THIJ-21-7558. [DOI] [PMC free article] [PubMed] [Google Scholar] [82] Porres-Aguilar M, Rosovsky RP, Rivera-Lebron BN, Kaatz S, Mukherjee D, Anaya-Ayala JE, et al. Pulmonary embolism response teams: Changing the paradigm in the care for acute pulmonary embolism. Journal of Thrombosis and Haemostasis: JTH. 2022;20:2457–2464. doi: 10.1111/jth.15832. [DOI] [PubMed] [Google Scholar] [84] Ryan L, Maharjan J, Mataraso S, Barnes G, Hoffman J, Mao Q, et al. Predicting pulmonary embolism among hospitalized patients with machine learning algorithms. Pulmonary Circulation. 2022;12:e12013. doi: 10.1002/pul2.12013. [DOI] [PMC free article] [PubMed] [Google Scholar] [85] Cantu-Martinez O, Martinez Manzano JM, Tito S, Prendergast A, Jarrett SA, Chiang B, et al. Clinical features and risk factors of adverse clinical outcomes in central pulmonary embolism using machine learning analysis. Respiratory Medicine. 2023;215:107295. doi: 10.1016/j.rmed.2023.107295. [DOI] [PubMed] [Google Scholar] [87] Farzaneh H, Junn J, Chaibi Y, Ayobi A, Franciosini A, Scudeler M, et al. Deep Learning-Based Algorithm for Automatic Detection of Incidental Pulmonary Embolism on Contrast-Enhanced Computed Tomography: A Multicenter Multivendor Study. Radiology Advances. 2025;2:umaf021. doi: 10.1093/radadv/umaf021. [DOI] [PMC free article] [PubMed] [Google Scholar] [42] Giraud R, Laurencet M, Assouline B, De Charrière A, Banfi C, Bendjelid K. Can VA-ECMO Be Used as an Adequate Treatment in Massive Pulmonary Embolism? Journal of Clinical Medicine. 2021;10:3376. doi: 10.3390/jcm10153376. [DOI] [PMC free article] [PubMed] [Google Scholar] [43] Pavlovic G, Banfi C, Tassaux D, Peter RE, Licker MJ, Bendjelid K, et al. Peri-operative massive pulmonary embolism management: is veno-arterial ECMO a therapeutic option? Acta Anaesthesiologica Scandinavica. 2014;58:1280–1286. doi: 10.1111/aas.12411. [DOI] [PubMed] [Google Scholar] [44] Corsi F, Lebreton G, Bréchot N, Hekimian G, Nieszkowska A, Trouillet JL, et al. Life-threatening massive pulmonary embolism rescued by venoarterial-extracorporeal membrane oxygenation. Critical Care (London, England). 2017;21:76. doi: 10.1186/s13054-017-1655-8. [DOI] [PMC free article] [PubMed] [Google Scholar] [45] Boey JJE, Dhundi U, Ling RR, Chiew JK, Fong NCJ, Chen Y, et al. Extracorporeal Membrane Oxygenation for Pulmonary Embolism: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2023;13:64. doi: 10.3390/jcm13010064. [DOI] [PMC free article] [PubMed] [Google Scholar] [46] Assouline B, Assouline-Reinmann M, Giraud R, Levy D, Saura O, Bendjelid K, et al. Management of High-Risk Pulmonary Embolism: What Is the Place of Extracorporeal Membrane Oxygenation? Journal of Clinical Medicine. 2022;11:4734. doi: 10.3390/jcm11164734. [DOI] [PMC free article] [PubMed] [Google Scholar] [47] Giraud R, Banfi C, Siegenthaler N, Bendjelid K. Massive pulmonary embolism leading to cardiac arrest: one pathology, two different ECMO modes to assist patients. Journal of Clinical Monitoring and Computing. 2016;30:933–937. doi: 10.1007/s10877-015-9796-2. [DOI] [PubMed] [Google Scholar] [48] Giraud R, Banfi C, Siegenthaler N, Bendjelid K. Massive pulmonary embolism leading to cardiac arrest: one pathology, two different ECMO modes to assist patients. Journal of Clinical Monitoring and Computing. 2016;30:933–937. doi: 10.1007/s10877-015-9796-2. [DOI] [PubMed] [Google Scholar] [49] EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AWA, Decousus H, Jacobson BF, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. The New England Journal of Medicine. 2012;366:1287–1297. doi: 10.1056/NEJMoa1113572. [DOI] [PubMed] [Google Scholar] [50] Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. The New England Journal of Medicine. 2013;369:799–808. doi: 10.1056/NEJMoa1302507. [DOI] [PubMed] [Google Scholar] [51] van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis: JTH. 2014;12:320–328. doi: 10.1111/jth.12485. [DOI] [PubMed] [Google Scholar] [53] Samama CM, Afshari A, Grønlykke L, Madsen MH, Wiberg S, Romero CS. European guidelines on peri-operative venous thromboembolism prophylaxis: first update.: Executive summary. European Journal of Anaesthesiology. 2024;41:561–569. doi: 10.1097/EJA.0000000000002025. [DOI] [PubMed] [Google Scholar] [54] Douketis JD, Spyropoulos AC, Murad MH, Arcelus JI, Dager WE, Dunn AS, et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2022;162:e207–e243. doi: 10.1016/j.chest.2022.07.025. [DOI] [PubMed] [Google Scholar] [39] Pruszczyk P, Klok FA, Kucher N, Roik M, Meneveau N, Sharp ASP, et al. Percutaneous treatment options for acute pulmonary embolism: a clinical consensus statement by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function and the European Association of Percutaneous Cardiovascular Interventions. EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2022;18:e623–e638. doi: 10.4244/EIJ-D-22-00246. [DOI] [PMC free article] [PubMed] [Google Scholar] [40] Bavalia R, Stals MAM, Mulder FI, Bistervels IM, Coppens M, Faber LM, et al. Use of the National Early Warning Score for predicting deterioration of patients with acute pulmonary embolism: a post-hoc analysis of the YEARS Study. Emergency Medicine Journal: EMJ. 2023;40:61–66. doi: 10.1136/emermed-2021-211506. [DOI] [PubMed] [Google Scholar] [41] Janata K, Lipa AJ, Merrelaar A, Merrelaar M, Azizi-Semrad U, Herkner H, et al. Enhancing Pulmonary Embolism Risk Stratification: The National Early Warning Score and Its Integration into the European Society of Cardiology Classification. Thrombosis and Haemostasis. 2025 doi: 10.1055/a-2544-3626. [DOI] [PMC free article] [PubMed] [Google Scholar] [276] STORM-PE trial (NCT05684796) [286] CLEAN-PE study (NCT06189313)
Keywords:
pulmonary embolism, PE management, PE treatment, innovations PE, future PE therapies, catheter-directed therapy, CDT, systemic thrombolysis, surgical embolectomy, anticoagulation, novel oral anticoagulants, NOACs, ultrasound-assisted CDT, UACDT, mechanical thrombectomy, PERT, machine learning PE, artificial intelligence PE, PE diagnosis, risk stratification PE, medical device, INVAMED, pulmonary embolism symptoms, PE diagnosis methods, PE treatment options, blood clot in lung, deep vein thrombosis, DVT, interventional cardiology, critical care, emergency medicine, cardiovascular health
Meta Description:
Explore the latest innovations and future directions in pulmonary embolism (PE) management, including advanced catheter-directed therapies, AI integration, and multidisciplinary approaches. Learn about evolving treatments and diagnostic tools for improved patient outcomes.